ArticleTheranostics2018

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.

Jiang-Kai Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.